- Home
- CGTX vs IVVD Comparison
CGTX vs IVVD Comparison
Compare CGTX & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- IVVD
- Stock Information
- Founded
- CGTX 2007
- IVVD 2020
- Country
- CGTX United States
- IVVD United States
- Employees
- CGTX N/A
- IVVD N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- CGTX Health Care
- IVVD Health Care
- Exchange
- CGTX Nasdaq
- IVVD Nasdaq
- Market Cap
- CGTX 53.4M
- IVVD 63.4M
- IPO Year
- CGTX 2021
- IVVD 2021
- Fundamental
- Price
- CGTX $1.61
- IVVD $1.26
- Analyst Decision
- CGTX Strong Buy
- IVVD Strong Buy
- Analyst Count
- CGTX 3
- IVVD 4
- Target Price
- CGTX $2.83
- IVVD $3.64
- AVG Volume (30 Days)
- CGTX 8.1M
- IVVD 15.0M
- Earning Date
- CGTX 11-12-2025
- IVVD 11-13-2025
- Dividend Yield
- CGTX N/A
- IVVD N/A
- EPS Growth
- CGTX N/A
- IVVD N/A
- EPS
- CGTX N/A
- IVVD N/A
- Revenue
- CGTX N/A
- IVVD $46,210,000.00
- Revenue This Year
- CGTX N/A
- IVVD $385.94
- Revenue Next Year
- CGTX N/A
- IVVD $62.62
- P/E Ratio
- CGTX N/A
- IVVD N/A
- Revenue Growth
- CGTX N/A
- IVVD 1941.08
- 52 Week Low
- CGTX $0.22
- IVVD $0.35
- 52 Week High
- CGTX $3.83
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- CGTX 42.22
- IVVD 62.22
- Support Level
- CGTX $1.43
- IVVD $1.05
- Resistance Level
- CGTX $2.60
- IVVD $1.45
- Average True Range (ATR)
- CGTX 0.32
- IVVD 0.18
- MACD
- CGTX -0.17
- IVVD 0.03
- Stochastic Oscillator
- CGTX 10.81
- IVVD 72.06
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.